Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis

Purpose: According to the IMvigor130 trial, adding atezolizumab to platinum-based chemotherapy was effective in the treatment of metastatic urothelial cancer (mUC). Based on the perspective of the United States and China, the current study evaluated cost-effectiveness of atezolizumab plus chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoyan, Lang, Yitian, Chai, Qingqing, Lin, Yan, Liao, Yahui, Zhu, Yizhun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441572/
https://www.ncbi.nlm.nih.gov/pubmed/36071854
http://dx.doi.org/10.3389/fphar.2022.872196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441572/
https://www.ncbi.nlm.nih.gov/pubmed/36071854
http://dx.doi.org/10.3389/fphar.2022.872196

Ejemplares similares